Categories
Science

Realme Electric Toothbrush sale starts today, check out details here

Realme has recently introduced the Realme M1 Sonic Electric Toothbrush in the country. This electric toothbrush has been received for sale for the first time today after its introduction. Realme’s electric toothbrush will be purchased by customers from Realme.com and Flipkart from 12 noon. The M1 electric toothbrush will come in two color options blue and white.

Realme M1 Sonic Electric Toothbrush is priced at Rs 1,999. Realme Electric Toothbrush, as well as two other products Realme Adventurer Luggage and Realme Tote Bag2, have been sold for sale today. Customers will also be able to purchase them at 12 noon today. Realme Adventurer Luggage is priced at Rs 2,999, while the Realme Tote Bag2 is priced at Rs 999.

Realme Adventurer Luggage and Realme Tote Bag2 can also be purchased from exclusive Realme.com. The Realme Electric Toothbrush will have four modes of soft, clean, white and polished. Consumers will be able to use these modes accordingly. Simultaneously, the toothbrush will receive information on battery life. This electric toothbrush will receive with a battery life of 90 days.

It can be used four times a year. It is provided with an 800mAh battery. Realme’s electric toothbrush can be charged in 4-5 hours with the help of a charger. The Realme M1 will be available with sonic electric toothbrush high-frequency sonic motor, which will generate a vibration rate of 3400 times per minute.

Categories
Technology

Now Realme 6 Pro smartphone will be revealed in a new style! Click here to know about the change

Realme 6 Pro is getting another software update, which brings bug fixes with the August 2020 Android Security Patch on the phone. Realme is rolling out the update in an OTA manner, but it is rolling out in a phased manner, which means that the update will initially be released to a limited number of users and will gradually be available to all Realme 6 Pro users.

Realme posted on its community forum that Realme 6 Pro is getting the RMX2061_11.A.31 software update as the UIX version number. This update has been released in the OTA way and Reality 6 Pro users who get this update will get notifications on the phone. However, if a notification is not received, users can still check it from within the settings.

Realme has claimed that many problems with this update have been fixed. The new software update adds a Super Nighttime standby and smooth scrolling feature to the settings. It also added super power saving mode, deep cleanup feature in Process Manager, icon pull-down gestures in the launcher and the ability to copy the device’s IMEI from the software information interface.

Categories
Business Healthcare

Serum Institute of India pauses COVID-19 vaccine trials after DCGI notice

The Serum Institute of India has paused trials till further instructions from the DCGI after getting a show-cause notice.

The phase 2/3 COVID-19 trials being conducted across 17 sites are paused till further orders.

The notice says: “Serum Institute of India, Pune, up till has not informed the central licencing authority regarding pausing the clinical trial carried out by AstraZeneca in other countries and also not submitted casualty analysis of the reported serious adverse event with the investigational vaccine for contribution of the Phase II/III clinical trial of the subject vaccine in the country in light of the safety concerns.”

The show-cause notice was issued following reports that human trials of the most promising COVID-19 vaccine candidate, being developed by the University of Oxford, have been put on hold after a UK participant had an adverse reaction to it.

The Drugs Controller General of India, Dr V G Somani, in his show-cause notice has asked SII as to why the permission granted for conducting phase 2 and 3 clinical trials of the vaccine candidate in the country be not suspended till patient safety is established.

“Whereas, Serum Institute of India Pvt Ltd, Pune, till now has not informed the central licensing authority regarding pausing the clinical trial carried out by AstraZeneca in other countries and also not submitted casualty analysis of the reported serious adverse event with the investigational vaccine for the continuation of phase 2 and 3 clinical trials of the subject vaccine in the country in light of the safety concerns,” said the show-cause notice accessed by PTI.

“In view of the above, I Dr V G Somani, Drugs Controller General of India and Central Licensing Authority hereby give you an opportunity to show cause as provided under rule 30 of the New Drugs and Clinical Trials Rules, 2019, why the permission granted to you August 2 shall not be suspended till patient safety is established,” the notice further said.

The DGCI sought an immediate reply, saying else “it shall be construed that you have no explanation to offer and action deemed fit will be taken against you”.

In the show-cause notice, the drug regulator also mentioned that the clinical trials have been put on hold across countries where they were conducted i.e. USA, UK, Brazil and South Africa.

Regarding the show cause notice issued by DCGI, Serum Institute of India (SII) said in a statement, “We are going by DCGI’s direction and so far were not told to pause the trials. If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocol.” Last month, the DCGI had granted permission to the Pune-based SII to conduct Phase 2 and 3 human clinical trials of the coronavirus vaccine candidate.

AstraZeneca, a British-Swedish biopharmaceutical giant in a tie-up with the Oxford University to produce the vaccine, described the pause of trials as a “routine” one following what was “an unexplained illness”. Earlier in the day, SII which has partnered with AstraZeneca for manufacturing the Oxford vaccine candidate for COVID-19, said it is continuing with the trials in India.

Commenting on the recent reports on AstraZeneca halting the trials in the UK, SII said in a statement, “We can’t comment much on the UK trials, but they have been paused for further review and they hope to restart soon.” It further said, “As far as Indian trials are concerned, it is continuing and we have faced no issues at all.”

Categories
Uncategorized

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!